Trial reportThe Journal of clinical endocrinology and metabolism2007
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
Trial report in The Journal of clinical endocrinology and metabolism, 2007. The graph read 1 number from its abstract, feeding 1 cell of the map: it finds no clear difference in 1. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
RESULTS: Consistent with prior cross-sectional studies, P/P homozygotes at PPARG P12A appeared more likely to develop diabetes than alanine carriers (hazard ratio, 1.24; 95% confidence interval, 0.99-1.57; P=0.07) with no interaction of genotype with intervention.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Cardiac procedures & devices×liver & masld
InconclusiveOpen on the map →What to test next →1 readable study in this cell: 0 favour the treatment, 1 find no difference, 0 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Gene-lifestyle interaction on risk of type 2 diabetes: A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2019Pooled it
- A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.Nature genetics · 2012Pooled it
- No interactions between previously associated 2-hour glucose gene variants and physical activity or BMI on 2-hour glucose levels.Diabetes · 2012Pooled it
- Pharmacogenetics of glucose-lowering drug treatment: a systematic review.Molecular diagnosis & therapy · 2007Pooled it
- Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial.Obesity (Silver Spring, Md.) · 2012Trial
- Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.Human genomics · 2008Trial
- The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.Diabetologia · 2007Trial
- Association of PPARγ (rs1801282) and TCF7L2 (rs7903146) gene polymorphisms and susceptibility of Type 1 diabetes mellitus in Egyptian children.Journal, genetic engineering & biotechnology · 2026Article
- Identification of antidiabetic inhibitors fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.The Journal of clinical endocrinology and metabolism · 2023Article
- PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.Current diabetes reports · 2021Review
- PPARγ2 Pro12Ala Polymorphism is Associated in Children With Traits Related to Susceptibility to Type 2 Diabetes.Frontiers in pharmacology · 2021Article
- Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- Computational determination of human PPARG gene: SNPs and prediction of their effect on protein functions of diabetic patients.Clinical and translational medicine · 2020Article
- Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine.Endocrine reviews · 2019Review
- Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.Nature communications · 2019Article
- Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.Diabetes/metabolism research and reviews · 2019Review
- Effects Of PPARγ2 Pro12Ala Variant On Adipocyte Phenotype Dependent Of DHA.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Extracting Complementary Insights from Molecular Phenotypes for Prioritization of Disease-Associated Mutations.Current opinion in systems biology · 2018Article
- Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders.Journal of developmental and behavioral pediatrics : JDBP · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
contextThe common P12A polymorphism in PPARG (a target for thiazolidinedione medications) has been consistently associated with type 2 diabetes.
objectiveWe examined whether PPARG P12A affects progression from impaired glucose tolerance to diabetes, or responses to preventive interventions (lifestyle, metformin, or troglitazone vs. placebo). PATIENTS: This study included 3548 Diabetes Prevention Program participants.
designWe performed Cox regression analysis using genotype at PPARG P12A, intervention, and their interactions as predictors of diabetes incidence. We also genotyped five other PPARG variants implicated in the response to troglitazone and assessed their effect on insulin sensitivity at 1 yr.
resultsConsistent with prior cross-sectional studies, P/P homozygotes at PPARG P12A appeared more likely to develop diabetes than alanine carriers (hazard ratio, 1.24; 95% confidence interval, 0.99-1.57; P=0.07) with no interaction of genotype with intervention. There was a significant interaction of genotype with body mass index and waist circumference (P=0.03 and 0.002, respectively) with the alanine allele conferring less protection in more obese individuals. Neither PPARG P12A nor five other variants significantly affected the impact of troglitazone on insulin sensitivity in 340 participants at 1 yr.
conclusionsThe proline allele at PPARG P12A increases risk for diabetes in persons with impaired glucose tolerance, an effect modified by body mass index. In addition, PPARG P12A has little or no effect on the beneficial response to troglitazone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.